Board Of Directors
David Evans (Non-Executive Chairman)
As the former CFO David Evans guided Shield Diagnostics Ltd. through its IPO and then, as its CEO, through its merger with Axis Biochemical ASA to form Axis-Shield plc, a fully listed diagnostics company. In addition to being Chairman of the Company he is currently non-executive Chairman of Epistem, Immunodiagnostic Systems Holdings plc and Omega Diagnostics Group plc, all of which are AIM listed biotechnology companies.
Professor Lindy Durrant (CEO)
An internationally recognised immunologist in the field of tumour therapy, Prof. Durrant has worked for 21 years in translational research, developing products for clinical trials including monoclonal antibodies for diagnostic imaging and therapy and cancer vaccines. She has a personal Chair in Cancer Immunotherapy at the Department of Clinical Oncology at the University of Nottingham and is currently running clinical trials in colorectal cancer and osteosarcoma.
Dr Richard Goodfellow (Chief Operating Officer)
Dr Richard Goodfellow has over 25 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company’s flotation on the London Stock Exchange and successfully negotiated numerous deals. Dr Goodfellow is also a founder of Paradigm Therapeutics, a Cambridge based functional genomics company and is a former Director of Enact Pharma plc.
Nigel Evans (Company Secretary)
Nigel Evans has 40 years commercial and strategic responsibilities at senior levels in Rolls-Royce plc in the UK and overseas. Now an active investor in public and private companies, he oversees Scancell’s corporate and financial activities. He was Executive Chairman of Scancell for seven years, until 2007, and was heavily involved with its progress during that period.
Michael Rippon
Mike Rippon has over 40 years experience in the motor industry. He is now an active investor in small private companies and is one of Scancell’s major private investors. He was appointed to the Board on 1 January 2004 as the Shareholder Representative.
Dr Matthew Frohn
Dr Matthew Frohn graduated from Oxford Brookes University with a degree in Cell and Molecular Biology followed by a D.Phil in Biochemistry from Oxford University. He worked on research collaborations with Astra Zeneca, and a short research post with a British Biotech subsidiary before joining Oxford Technology Management in 1999, the manager of the Oxford Technology VCTs.